Get the latest tech news
Tufts Medical Center Research Uncovers Breakthrough Strategy to Reprogram Prostate Cancer
New therapy reprograms prostate cancer to boost immune attack
For the past 16 years, Paul Mathew, MD, Hematologist/Oncologist at Tufts Medical Center, has dedicated his career to unraveling the molecular mechanisms that drive prostate cancer. Now, in a recently published study, Dr. Mathew and his research team have introduced a novel bispecific antibody that targets two integrins—receptors that not only fuel the aggressiveness of prostate tumors but also help them hide from the immune system. The research challenges long-held assumptions about “precision medicine” approaches to cancer treatment, which effectively ignore the tumor’s lethal hard-wiring controlled by integrins.
Or read this on r/technology
